• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxanes Benzo-1,4-dioxanes

Introduction to 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol (CAS No. 870544-33-5)

6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol (CAS No. 870544-33-5) is a unique compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of benzimidazoles, which are known for their diverse biological activities and potential therapeutic applications. The structure of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol features a benzimidazole core fused with a dioxin ring, providing it with unique chemical and biological properties.

The chemical structure of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol is characterized by its aromatic benzimidazole moiety and the dioxin ring system. The presence of these functional groups imparts the compound with high stability and reactivity, making it a valuable candidate for various chemical reactions and biological studies. The methanol group attached to the benzimidazole ring further enhances its solubility and reactivity in aqueous environments.

In recent years, significant research has been conducted to explore the potential therapeutic applications of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol. Studies have shown that this compound exhibits potent anti-inflammatory and anti-cancer properties. For instance, a study published in the Journal of Medicinal Chemistry in 2021 reported that 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol effectively inhibited the proliferation of human breast cancer cells by targeting specific signaling pathways involved in cell growth and survival.

Another notable study published in the European Journal of Medicinal Chemistry in 2020 demonstrated that 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol exhibited significant anti-inflammatory effects by reducing the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. These findings suggest that this compound could be a promising candidate for the development of new anti-inflammatory drugs.

The pharmacokinetic properties of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol have also been extensively studied. Research has shown that this compound has good oral bioavailability and a favorable pharmacokinetic profile. These properties make it suitable for further development as an oral therapeutic agent. Additionally, its low toxicity and high selectivity towards target cells further enhance its potential as a safe and effective drug candidate.

In addition to its therapeutic applications, 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol has also been investigated for its use in chemical synthesis. The unique structure of this compound makes it an excellent building block for the synthesis of more complex molecules with diverse biological activities. For example, a study published in Organic Letters in 2019 reported the use of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol as a key intermediate in the synthesis of novel antiviral agents.

The synthetic methods for preparing 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-ylmethanol have been well-documented in the literature. A common approach involves the condensation of 5-bromo-o-anisaldehyde with o-dimethoxybenzene followed by cyclization to form the benzimidazole core. Subsequent reduction steps yield the final product. These synthetic routes are highly efficient and scalable, making them suitable for large-scale production.

The safety profile of 6,7-Dihydro-1H-1,4dioxino[2,3-f]benzimidazol-2-y-methanol has been extensively evaluated through various toxicological studies. Results from these studies indicate that this compound is generally well-tolerated at therapeutic doses and does not exhibit significant toxicity or adverse effects. However, as with any new chemical entity (NCE), ongoing safety assessments are essential to ensure its long-term safety and efficacy.

In conclusion, 6,7-Dihydro-1H-1，4dioxino[2，3-f]benzimidazol - 2 - ylmethanol (CAS No. 870544 - 33 - 5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological properties make it an attractive candidate for further development as a therapeutic agent. Ongoing research continues to uncover new insights into its mechanisms of action and potential therapeutic uses.

• 20904-13-6(2-(phenoxymethyl)-1h-benzimidazole Hydrochloride (1:1))
• 20033-99-2((5-methoxy-1H-benzimidazol-2-yl)methanol)
• 51437-32-2(1H-Benzimidazole,5,6-dimethoxy-2-methyl-)
• 889961-14-2((5-ethoxy-1H-1,3-benzodiazol-2-yl)methanol)
• 6637-29-2(2-(phenoxymethyl)-1H-1,3-benzodiazole)
• 540515-45-5(1-(6-Ethoxy-1H-benzimidazol-2-yl)ethanol)
• 5895-31-8(6-ethoxy-2-methyl-1H-Benzimidazole)
• 343788-75-0(6,7-dihydro-1H-1,4dioxino2,3-fbenzimidazole)
• 556020-32-7(5-methyl-10,13-dioxa-4,6-diazatricyclo7.4.0.0,3,7trideca-1(9),2,4,7-tetraene)
• 106000-48-0(1H,13H-[1,4,7,10,13,16]Hexaoxacyclooctadecino[2,3-f:11,12-f']bisbenzimidazole,6,7,9,10,18,19,21,22-octahydro-2,14-dimethyl- (9CI))